Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 30, 2013
Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysisMadan Jagasia, Hildegard Greinix, Marie Robin, et al.
British Journal of Haematology|November 28, 2023
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trialMhairi Copland, Cono Ariti, Ian F Thomas, et al.
Blood|May 10, 2003
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myelomaPaolo Corradini, Michele Cavo, Henk Lokhorst, et al.
Transfusion|October 31, 2009
Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantationGeoff Lucas, Steven Culliford, Frances Green, et al.
Haematologica|July 23, 2026
Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML TrialCarlos Jiménez-Vicente, Jad Othman, Nicola Potter, et al.
Haematologica|June 1, 2005
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trialNorbert Schmitz, Meral Beksac, Andrea Bacigalupo, et al.
Blood|March 26, 2015
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemiaMike Dennis, Nigel Russell, Robert K Hills, et al.
Leukemia Research|May 3, 2014
Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphomaVictor Noriega, Harpreet Kaur, Stephen Devereux, et al.
Blood|November 23, 2016
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AMLSteven Knapper, Nigel Russell, Amanda Gilkes, et al.
British Journal of Haematology|March 26, 2013
Does BCR/ABL1 positive acute myeloid leukaemia exist?Ellie P Nacheva, Colin D Grace, Diana Brazma, et al.
Pageof 12